ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NCNA / insiders
XTLB (46) TRAW (31) DRMA (34) APUS (37) ⌘ Pro Terminal →

NuCana plc (NCNA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.01 -2.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.00

NuCana plc (NCNA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $4.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NCNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NCNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NuCana plc (NASDAQ: NCNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.01 (-2.88% 1D, market cap $4.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NCNA ranks #352 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NCNA compare to XTLB and TRAW in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XTLB (XTL Biopharmaceuticals Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $4.0M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, NCNA leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NCNA?
▼

For NuCana plc (NCNA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #352 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.00 (-0.71%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE NCNA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NCNA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY NCNA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($117.7K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.05-3.8% Next Q
Q2 (-2Q)
51
Grade C-$1.01+8.9% Next Q
Q3 (-1Q)
49
Grade D$1.10-8.2% Next Q
Current
46
Grade D$1.01-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NCNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NCNA currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.22) and Max Pain ($1.06) forces dealer call-delta covering toward $4.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NCNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NCNA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NCNA Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NCNA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NCNA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NCNA)

  • ✓Walkthrough of NCNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NCNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.30%▼ DESCENDING CHANNEL
2026-11-03O $1.04H $1.04L $1.01C $1.01VOL 19.2K
RES: $1.55SUP: $0.85SMA50: $1.22SMA200: $1.73
$3.90$3.10$2.30$1.50$0.70RES $1.55SUP $0.85$1.012026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NCNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NCNA Butterfly Map → + Track NCNA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NCNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NCNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NCNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NCNA)

Health Care Rank #352 of 1016 ⚔️ XTLB vs NCNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NCNA vs. XTLB, TRAW, DRMA, APUS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NuCana plc (NCNA) ranks #352 by composite RQD confidence (46/100, grade D) and #955 by equity capitalization ($4.2M). Within this direct 5-issuer industry benchmark cohort, NCNA leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. NCNA currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NCNA ACTIVE
NuCana plc
D 46/100 — — — -2.88% $4.2M Benchmark Subject
XTLB
XTL Biopharmaceuticals Ltd.
D 46/100 — — — -8.52% $4.0M /xtlb-vs-ncna →
TRAW
Traws Pharma Inc.
E 31/100 — — -35.0% -1.66% $4.5M /traw-vs-ncna →
DRMA
Dermata Therapeutics Inc.
E 34/100 — — -35.0% -7.86% $3.8M /drma-vs-ncna →
APUS
Apimeds Pharmaceuticals US Inc.
D- 37/100 — — -6.2% -6.23% $4.6M /apus-vs-ncna →

2. NCNA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

NuCana plc (NCNA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NCNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NCNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NuCana plc (NASDAQ: NCNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.01 (-2.88% 1D, market cap $4.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NCNA ranks #352 in composite RQD confidence.

How does NCNA compare to XTLB and TRAW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XTLB (XTL Biopharmaceuticals Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $4.0M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, NCNA leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NCNA?

For NuCana plc (NCNA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #352 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NCNA trading relative to its 50-day, 200-day, and 52-week technical levels?

NCNA last traded at $1.01 (-2.88% on volume of 19,234 shares), positioning the stock -17.21% below its 50-day simple moving average ($1.22) and -41.62% below its 200-day simple moving average ($1.73). Across its 52-week range of $0.95 to $4.55, NCNA sits at the 1.7% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

NCNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NCNA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NCNA leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: NCNA RQD Cockpit NCNA 12M Forecast NCNA Earnings & Move NCNA Dividends & DRIP NCNA Insiders & 13F NCNA Whale Options NCNA Profit Sankey NCNA News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NCNA — NuCana plc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:20:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NuCana plc scores 46 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. The pillar notes ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the rating finds no measurable return on invested capital and no free-cash-flow yield to support the valuation today.
  • Whale 13F Flow: 3 / 20. This is the weakest pillar, covering institutional accumulation and options positioning. The low score indicates the rating does not identify meaningful institutional accumulation.
  • Insider Conviction: 9 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The score reflects limited supportive insider signaling.
  • Macro Regime Fit: 9 / 20. The pillar reports Beta of 1.0 and sector sensitivity. Investors should understand that the rating does not show a favorable macro-regime alignment.
  • Forensic Balance Sheet: 13 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, but it still reflects only moderate balance-sheet quality.

Taken together, the rating's pillars point to an absence of cash generation and institutional support, partly offset by a moderate balance sheet. Valuation tradeoffs are significant: with a market capitalization of $4.3M and no reported earnings or cash-flow yield, the price of 1.04 is not anchored to measurable profitability in the source data. Upside drivers, if any, are not identified within the rating itself; the bear case rests on the weak whale-flow and cash-engine pillars.

Recent Catalysts & News Wire Analysis

Per the recent news wire, six items were reported, all referencing NCNA market action and fundamental catalysts:

  • A TradingView estimates report (YELLOW, MARKET WIRE).
  • An ad-hoc-news.de report on Edison listing a ProTide oncology focus (YELLOW, MARKET WIRE).
  • Three Traders Union reports describing price moves on buyer follow-through and intraday support, two of which are tagged GREEN CATALYST and one YELLOW MARKET WIRE.
  • A Traders Union report asking why the stock rose 7.5% (YELLOW, MARKET WIRE).

Risk watch items: the wire headlines describe weak follow-through from buyers, and the price is down -3.26% on the day. The most concrete fundamental catalyst referenced is the ProTide oncology focus; the source does not detail its commercial or clinical status. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Open Questions

  • What are the company's reported revenue, net income, and cash position, given that no financial statements are in the source data?
  • What is the status and commercial pathway of the ProTide oncology focus referenced in the news wire?
  • Why do the RQD whale-flow and insider pillars score so low, and what institutional or insider filings underlie that assessment?
  • What explains the 52-week range of $0.95 to $4.55 relative to the current price of 1.04?
  • What is the company's cash runway and financing position given its $4.3M market capitalization and zero reported cash-flow yield?

NCNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NuCana plc (NCNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NCNA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NCNA Bull vs. Bear Conversation Board — What's Your Call at $1.01?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NCNA 🐻 50% BEARISH CONVICTION
1. Pick Your Side on NCNA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.12 (+7.7%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NCNA (D • RQD 46/100) a Buy at $1.04?

Welcome to the NCNA (NuCana plc) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.87 (-16.3%)
Spot @ $1.04

Pump the brakes on NCNA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NCNA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NuCana plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.24 (+19.2%)
Spot @ $1.04

NCNA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NCNA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.04 (52-wk range $0.95 - $4.55), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%